Furthermore, 24 h after transfection, cells were treated with a series dose of TMZ (7.5, 15, 30, 60, 120, 240, and 480 μM) for 24 h; the cell viability was then determined using MTT assays to assess the combined effect of XIST and miR-29c on glioma cell chemoresistance to TMZ. The gene discussed is XIST; the disease is central nervous system cancer.